DR
TMO icon

Davis Rea’s Thermo Fisher Scientific TMO Stock Holding History

Davis Rea’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.7M Buy
33,605
+47
+0.1% +$27.9K 5.98% 7
2026
Q2 		$16.8M Buy
33,558
+5,373
+19% +$2.58M 4.8% 7
2026
Q1 		$13.9M Buy
28,185
+653
+2% +$354K 3.61% 7
2025
Q4 		$16M Sell
27,532
-10,976
-29% -$6.21M 4% 6
2025
Q3 		$18.7M Sell
38,508
-4,786
-11% -$2.23M 4.54% 6
2025
Q2 		$17.6M Buy
43,294
+5,582
+15% +$2.33M 4.36% 6
2025
Q1 		$18.8M Buy
37,712
+8,452
+29% +$4.58M 5% 6
2024
Q4 		$15.2M Buy
29,260
+17,231
+143% +$9.47M 7.71% 3
2024
Q3 		$7.45M Sell
12,029
-4,972
-29% -$2.94M 3.24% 14
2024
Q2 		$9.41M Sell
17,001
-2,432
-13% -$1.39M 4.7% 9
2024
Q1 		$11.3M Sell
19,433
-427
-2% -$240K 5.15% 9
2023
Q4 		$10.5M Buy
19,860
+4,331
+28% +$2.1M 5.4% 6
2023
Q3 		$7.87M Buy
15,529
+19
+0.1% +$10.1K 4.26% 8
2023
Q2 		$8.1M Buy
15,510
+4,964
+47% +$2.68M 4.54% 7
2023
Q1 		$6.08M Sell
10,546
-180
-2% -$101K 3.67% 11
2022
Q4 		$5.91M Sell
10,726
-120
-1% -$63.6K 3.7% 11
2022
Q3 		$5.5M Sell
10,846
-10,874
-50% -$6.09M 3.53% 11
2022
Q2 		$11.8M Buy
21,720
+6,351
+41% +$3.5M 3.51% 10
2022
Q1 		$5.12M Buy
15,369
+7,766
+102% +$4.46M 2.48% 17
2021
Q4 		$5.08M Buy
7,603
+24
+0.3% +$15K 2.36% 18
2021
Q3 		$4.33M Buy
7,579
+10
+0.1% +$5.49K 2.12% 20
2021
Q2 		$3.82M Buy
7,569
+121
+2% +$57.1K 1.9% 21
2021
Q1 		$3.4M Buy
7,448
+664
+10% +$317K 1.82% 21
2020
Q4 		$3.16M Buy
6,784
+170
+3% +$79.7K 1.78% 24
2020
Q3 		$2.92M Buy
6,614
+87
+1% +$35.9K 1.96% 20
2020
Q2 		$2.37M Sell
6,527
-37
-0.6% -$12.4K 1.8% 22
2020
Q1 		$1.86M Buy
6,564
+155
+2% +$48.9K 1.8% 22
2019
Q4 		$2.08M Buy
6,409
+254
+4% +$77K 1.42% 26
2019
Q3 		$1.79M Buy
6,155
+1,244
+25% +$356K 1.31% 26
2019
Q2 		$1.44M Buy
+4,911
New +$1.35M 0.83% 36

Other funds holding TMO

Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Sarasin & Partners
Sarasin & Partners London, United Kingdom $8.93B AUM 11.81% 1-Year Est. Return
James Hambro & Partners
James Hambro & Partners London, United Kingdom $2.87B AUM 19.92% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return
Perpetual Ltd
Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return
Guyasuta Investment Advisors
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.91B AUM 26.66% 1-Year Est. Return
Caledonia Investments plc (UK)
Caledonia Investments plc (UK) London England, United Kingdom $890M AUM 1.23% 1-Year Est. Return
MN Services Vermogensbeheer
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Davis Rea's TMO Position: Q3 2026 in Review

Davis Rea increased its Thermo Fisher Scientific (TMO) stake by 0.14% in Q3 2026, buying an estimated $27.9K and bringing the position to 33,605 shares worth $22.7M. The position accounts for 5.98% of the portfolio, ranked #7.

Davis Rea first reported a position in TMO in Q2 2019 and has held it in 30 quarters since. 507 funds tracked by Wall St. Rank hold TMO as of Q3 2026.

  • Davis Rea held 33,605 shares of Thermo Fisher Scientific worth $22.7M as of Q3 2026.
  • Davis Rea bought 47 Thermo Fisher Scientific shares in Q3 2026, an estimated $27.9K.
  • Thermo Fisher Scientific made up 5.98% of Davis Rea's portfolio in Q3 2026, its #7 holding.
  • Davis Rea first reported a position in Thermo Fisher Scientific in Q2 2019 and has held it in 30 quarters since.
  • 507 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2026.

Based on Davis Rea's 13F filing for Q3 2026, filed 13 Oct 2026.